Form 4: Acadia Pharmaceuticals Director Edmund Harrigan Reports Stock Transactions

Director Edmund Harrigan reports the vesting and disposition of restricted stock units and the grant of stock options in Acadia Pharmaceuticals.

Summary

• On May 29, 2024, Edmund Harrigan, a director of Acadia Pharmaceuticals, reported transactions involving the company's stock.
• Harrigan disposed of 6,652 shares of common stock following the vesting of restricted stock units.
• He also acquired 15,959 stock options with an exercise price of $14.62, vesting quarterly over one year and expiring on May 28, 2034.
• Additionally, Harrigan acquired 9,387 restricted stock units that will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.
• Following these transactions, Harrigan directly owns 25,654 shares of common stock, 15,959 stock options, and 9,387 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The grant of stock options and restricted stock units to a director aligns their interests with those of the shareholders.
• The vesting schedule of the stock options (quarterly over one year) encourages continued service and performance.

Industry Context

Form 4 filings are standard practice for reporting insider transactions and provide transparency to investors regarding the actions of company directors and officers.

Stakeholder Impact

• Shareholders gain insight into the trading activities of a company director, which can influence investor sentiment.

Key Dates